You just read:

Epygenix Therapeutics Receives US FDA Orphan Drug Designation for EPX-300 for the Treatment of Patients With Dravet Syndrome

News provided by

Epygenix Therapeutics, Inc.

Aug 23, 2017, 08:00 ET